Method of promoting bone growth by an anti-actriia antibody

Abstract

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

1 . A method for promoting bone growth, increasing bone density, or increasing bone strength, the method comprising administering to a subject in need thereof an effective amount of an anti-ActRIIa antibody. 
     
     
         2 . The method of  claim 1 , wherein the anti-ActRIIa antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 1 , wherein the anti-ActRIIa antibody is a humanized or fully human antibody. 
     
     
         4 . The method of  claim 1 , wherein the method is for promoting bone growth in a subject in need thereof. 
     
     
         5 . The method of  claim 1 , wherein the method is for increasing bone density in a subject in need thereof. 
     
     
         6 . The method of  claim 1 , wherein the method is for increasing bone strength in a subject in need thereof. 
     
     
         7 . The method of  claim 1 , wherein the method further comprises administering a second bone-active agent. 
     
     
         8 . The method of  claim 7 , wherein the bone-active agent is selected from: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 
     
     
         9 . A method for treating a bone-related disorder, the method comprising administering to a subject in need thereof an effective amount of an anti-ActRIIa antibody, wherein the bone-related disorder is associated with low bone density or decreased bone strength. 
     
     
         10 . The method of  claim 9 , wherein the anti-ActRIIa antibody is a monoclonal antibody. 
     
     
         11 . The method of  claim 9 , wherein the anti-ActRIIa antibody is a humanized or fully human antibody. 
     
     
         12 . The method of  claim 9 , wherein the method further comprises administering a second bone-active agent. 
     
     
         13 . The method of  claim 12 , wherein the bone-active agent is selected from: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 
     
     
         14 . The method of  claim 9 , wherein the bone-related disorder is primary osteoporosis. 
     
     
         15 . The method of  claim 9 , wherein the bone-related disorder is post-menopausal osteoporosis. 
     
     
         16 . The method of  claim 9 , wherein the bone-related disorder is secondary osteoporosis. 
     
     
         17 . The method of  claim 9 , wherein the bone-related disorder is hypogonadal bone loss. 
     
     
         18 . The method of  claim 9 , wherein the subject has a cancer that is associated with bone loss. 
     
     
         19 . The method of  claim 9 , wherein the subject is the recipient of a cancer treatment regimen than is associated with bone loss. 
     
     
         20 . The method of  claim 9 , wherein the bone-related disorder is bone metastases. 
     
     
         21 - 23 . (canceled)